

United States Patent and Trademark Office
- Sales Receipt -

01/10/2006 FPATTERS 00000002 503231 10509633

01 FC:1202 150.00 DA

RECEIVED
CENTRAL FAX CENTER

DEC 22 2005



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/509,633	Applicant: Jean-Claude Arnould
371 Filing Date: 09/29/2004	Attorney Docket No.: 100467-1P US
Examiner: Grazier, Nyeemah	Group Art Unit : 1626
Customer No.: 44992	Confirmation No.: 4294
Title: INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY	

I hereby certify that this correspondence is being facsimile transmitted
to the United States Patent and Trademark Office on 22 December
2005

Signature
Lucy Padget

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT

Sir:

In response to the Non-Final Office Action dated 12/13/2005, please amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks/Arguments begin on page 8 of this paper.

AstraZeneca R&D Boston
A business unit of AstraZeneca Pharmaceuticals LP
35 Gatehouse Drive
Waltham MA 02451

Tel +1 781-839-4000
Fax +1 781-839-4500

Page 1 of 9

Application No. 10/508,633
Amendment Dated 12/22/2005
Reply to Office Action of 12/1/2005

The Examiner also asked, for the purposes of searching, for an election of an exact definition within each of the substituents. For this purpose we elect:

- R¹ is C₁₋₄alkoxy (specifically methoxy);
- X is —S—;
- R² is hydrogen;
- R⁴ is carbamoyl;
- R⁵ is C₁₋₄alkyl (specifically methyl);
- p is 0; and
- q is 3.


Applicants also elect Example 18 as the single compound.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested

The Commissioner is hereby authorized to charge \$150 for excess claim fees. Please charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100467-1P US.

Respectfully submitted,



Name: Lucy Padget
Dated: December 22, 2005
Reg. No.: L0074
Phone No.: 781-839-4182

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451

Enclosed Supplemental ADS
 Annotated ADS.

Page 9 of 9

PAGE 1515 : RCV'D AT 12/22/2005 2:10:28 PM (Eastern Standard Time) : SVR:USPTO-EFXRF-6/28 : DNI:2738300 : CSID:17818394121 : DURATION (mm:ss):04:04